Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...

Moderna has outlicensed a rare disease drug candidate to Recordati, accepting $50 million upfront for an asset that could deliver registrational data this year.

In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Moderna, Inc. (NASDAQ:MRNA) is one of the stocks Jim Cramer was recently asked about. Noting that the company is working on a ...

Moderna agreed to work with Recordati in a deal worth up to $160 million to advance development of a drug designed to treat the metabolic disorder propionic acidemia.

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 ...

RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...